Industry news that matters to you.  Learn more

Revalesio Partners with Predictive Biomarker Sciences to Assess Potential Cancer Treatment

Reading time: 2 – 3 minutes

Revalesio Corporation announced today that it has contracted with Predictive Biomarker Sciences (PBS-Bio) to conduct studies related to the use of Revalesio’s novel anti-inflammatory therapeutic in treating cancer.

To jump-start drug development, PBS-Bio’s analysis helps pharmaceutical companies better understand how their drugs work and identifies biomarkers that can help predict which patients will respond to treatment.

“We’re developing a new technology that has novel anti-inflammatory effects applicable to a broad range of diseases,” said Dr. Richard Watson, director of Clinical Science at Revalesio, based in Tacoma. “Working with PBS-Bio, we want to further investigate how our technology alters cell survival in a number of different cancer lines, specifically looking at the connection of specific signaling pathways to inflammatory processes and proliferation signaling in oncology.”

A biomedical company based in Tacoma, Revalesio is advancing an entirely new class of therapeutics that disrupts inflammatory pathways. The company’s pioneering research, including an ongoing clinical trial for asthma, shows strong clinical efficacy with a remarkable lack of toxicity.

In addition to its work with PBS-BIO, Revalesio is developing treatments for cardiovascular disease, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease and other inflammatory mediated diseases.

PBS-Bio will provide Revalesio with unique real-time looks at how its therapeutics actually work over time within cellular pathways — the so-called mechanisms of action, said Dr. Edward Smith, co-founder and CEO of PBS-Bio, based in Mesa, Ariz.

The analysis will support Revalesio’s efforts to develop novel therapeutic candidates containing “charged-stabilized nanostructures” to prevent inflammation and treat inflammatory mediated diseases without inhibiting normal cellular functions.

Charge-stabilized nanostructures (CSNs) are aqueous-based nano-bubble cores surrounded by a stable molecular scaffolding. CSNs interact with cells, specifically naive immune cells, altering the surface of the cell membrane and preventing unwanted downstream cellular activity that causes inflammation.

“The charged-stabilized nanostructure is a platform from which we can create a variety of products as combination therapies or standalone therapeutics,” Dr. Watson said.

PBS-Bio is helping companies develop therapies against a variety of cancers. Most new cancer drugs fail in late-stage studies, and it can take as much as $1 billion and more than a decade to bring the drugs to market.

Source: Revalesio